Ascendis achieves surprisingly positive trial data and issues shares for millions
This week, Danish Ascendis Pharma announced its aim to raise over USD 460 million in a public offering of shares after the company achieved very positive phase III data for its main asset. The share price increased by 74 percent.
Danish biotech company Ascendis Pharma, which is listed on Nasdaq in the US, is issuing American Depositary Shares (ADSs), each of which represents one ordinary share of the company, to raise an initial USD 400 million.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Ascendis Pharma joins international biotech index
For abonnenter
